Catalyst Funds Management Pty Ltd Purchases Shares of 35,200 Moderna, Inc. (NASDAQ:MRNA)

Catalyst Funds Management Pty Ltd purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 35,200 shares of the company's stock, valued at approximately $1,464,000.

Other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the 4th quarter worth $37,000. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after buying an additional 388 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 1.4 %

NASDAQ:MRNA traded down $0.49 during trading hours on Wednesday, hitting $33.32. 6,304,090 shares of the stock traded hands, compared to its average volume of 6,561,969. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The company has a market cap of $12.86 billion, a price-to-earnings ratio of -3.59 and a beta of 1.86. The stock has a 50 day moving average price of $35.51 and a 200 day moving average price of $46.55.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MRNA shares. Argus lowered Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a report on Wednesday, January 15th. Finally, Leerink Partners reduced their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.